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Preliminary Investigation of Cardiovascular–Renal Disorders in
Dogs with Chronic Mitral Valve Disease
E. Martinelli, C. Locatelli, S. Bassis, S. Crosara, S. Paltrinieri, P. Scarpa, I. Spalla, AM. Zanaboni,
C. Quintavalla, and P. Brambilla
Background: Veterinary literature lacks data about cardiovascular–renal disorders (CvRD) and cardiorenal-anemia syn-
drome (CRAS) in dogs.
Hypothesis: A direct correlation exists between ACVIM class and IRIS stage; chronic kidney disease (CKD) complicates
chronic mitral valve disease (CMVD) more often than does anemia in dogs.
Animals: One hundred and ﬁfty-eight client-owned dogs with CMVD.
Methods: Signalment, physical examination ﬁndings, electrocardiography, thoracic radiographs, echocardiography, and
blood analysis were retrospectively evaluated to assess the prevalence of CKD and anemia in dogs with CMVD and to inves-
tigate the relationships among ACVIM class, IRIS stage, and survival.
Results: The prevalence of CKD and anemia in dogs with CMVD was signiﬁcantly higher than in the general population
of dogs. Dogs being treated for heart failure had a signiﬁcantly higher prevalence of CKD than did dogs that had not
received treatment. A statistically signiﬁcant direct correlation was found between ACVIM class and IRIS stage. Severe heart
disease, severe renal disease or both, furosemide administration, and advanced age at diagnosis of heart disease were associ-
ated with shorter survival time. Survival time of dogs aﬀected by CvRD was statistically shorter than survival time of dogs
aﬀected by CMVD alone.
Conclusion and Clinical Relevance: Chronic mitral valve disease is associated with increased prevalence of CKD and ane-
mia in dogs. Treatment for medical management of heart failure may play a role in inducing CKD. Class of heart disease
and IRIS stage were directly correlated. Cardiovascular–renal disorders decrease survival time compared to the only presence
of CMVD alone, whereas anemia does not play a central role in worsening heart function.
Key words: Anemia; Cardiorenal syndrome; Cardiovascular–renal disorders; Chronic kidney disease; Clinical pathology;
Endocardiosis; Heart disease; Hematology.
Recently, the ﬁeld of human medicine has been chal-lenged by a dual epidemic of heart failure and
renal insuﬃciency.1 Many hospitalized patients have
various degrees of heart and kidney dysfunction. Pri-
mary disorders of 1 of these 2 organs often result in
secondary dysfunction or injury to the other.2 The pres-
ence of the two problems in the same patient is referred
as cardiorenal syndrome (CRS), currently deﬁned in
dogs and cats as cardiovascular–renal disorders (CvRD)
by the CRS Consensus Group.3 Five subtypes of CRS
are described in the literature: CRS type 1 (acute CRS),
characterized by a rapid worsening of cardiac function,
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Abbreviations:
AoGmax aortic peak gradient
AoVmax aortic peak velocity
BSA body surface area
BW body weight
CBC complete blood count
CMVD chronic mitral valve disease
CRAS cardiorenal-anemia syndrome
CRS cardiorenal syndrome
CRS cardiorenal syndrome
CRAS cardiorenal-anemia syndrome
CMVD chronic mitral valve disease
CKD chronic kidney disease
CvRD cardiovascular–renal disorders
d diastole
EDVI end diastolic volume index
EF% left ventricular ejection fraction
ESVI end systolic volume index
EVmax E peak velocity
FS% fractional shortening
Hb hemoglobin
HF heart failure
HR heart rate
Hr hazard ratio
Ht hematocrit
IVS interventricular septal thickness
LA left atrial diameter
Ao aortic root diameter
LA/Ao left atrial to aortic root ratio
LVEDDn normalized left ventricular end diastolic diameter
calculated according to Cornell’s method of allometric
scaling
LVID left ventricular internal diameter
LVPW left ventricular posterior wall thickness
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leading to acute kidney injury; CRS type 2 (chronic
CRS), characterized by chronic abnormalities in cardiac
function causing progressive chronic kidney disease
(CKD); CRS type 3 (acute renocardiac syndrome), char-
acterized by an abrupt and primary worsening of kidney
function, leading to acute cardiac dysfunction; CRS type
4 (chronic renocardiac syndrome), characterized by a
condition of primary CKD contributing to decreased car-
diac function, ventricular hypertrophy, diastolic dysfunc-
tion, an increased risk of adverse cardiovascular events,
or some combination of these; and, CRS type 5 (sec-
ondary CRS), characterized by the presence of combined
cardiac and renal dysfunction associated with acute or
chronic systemic disorders.2 Furthermore, anemia is
often associated with heart failure (HF) and renal insuﬃ-
ciency in human medicine.3 Cardiorenal syndrome with
anemia forms a triad described as cardiorenal-anemia
syndrome (CRAS). Chronic kidney disease has an esti-
mated prevalence of 45–63% among human patients with
chronic heart failure (CHF), whereas little information
concerning the prevalence of renal dysfunction in dogs
with naturally occurring HF is available.4,5
The prevalence of azotemia in dogs with heart disease
varies, according to the veterinary literature, between
7.4 and 24.1%.a,4–8 The prevalence of anemia in human
patients with HF varies between 10 and 49%, as com-
pared to the 8.1–22.8% range reported in dogs with
heart disease.a,8–10 The most common heart disease
aﬀecting dogs and leading to CHF, is chronic mitral
valve disease (CMVD), also known as endocardiosis
and myxomatous valve degeneration.11 The aims of our
study were to assess the prevalence of CKD associated
with azotemia and the prevalence of anemia complicat-
ing CMVD in dogs, to evaluate a possible connection
between the class of cardiac disease (ACVIM classiﬁca-
tion) and the class of renal disease (IRIS staging sys-
tem), to investigate the correlation among the main
variable of the IRIS staging system, echocardiographic
variables and laboratory variables and evaluate diﬀer-
ences in survival time among dogs aﬀected by CMVD,
CvRD, and CRAS.
Materials and Methods
Two-thousand two-hundred and seventy-one medical records of
dogs presented to the Cardiology Service of the Department of
Veterinary Science and Public Health, University of Milan,
between January 2003 and December 2012 were evaluated
retrospectively.
The inclusion criteria were: dogs with complete clinical exami-
nation (including signalment, history, and physical examination),
thoracic radiographs, a CMVD diagnosis based on echocardio-
graphic examination (presence of mitral leaﬂet thickening, pro-
lapse, or both associated with an abnormal mitral regurgitant jet
on Doppler color ﬂow imaging) performed by a trained observer,
electrocardiogram (ECG) and laboratory test results (CBC and
serum biochemistry panel, including serum creatinine [sCr] and
serum urea concentrations [UREA]).11,12 Patients with azotemia
must have had complete urine analysis performedto be included.
The exclusion criteria were: other heart disease, neoplasm, or sys-
temic diseases such as hyperadrenocorticism and diabetes mellitus.
Patients suspected to have prerenal or postrenal azotemia (eg,
dehydration supported by CBC and biochemical analysis, con-
comitant urinary tract obstruction) were excluded. Greyhounds,
working dogs, or dogs receiving a high protein diet were excluded.
Dogs were categorized according to ACVIM classiﬁcation and
IRIS staging system and divided into 2 groups: treatment group
(TG) and no-treatment group (NTG) according to the presence or
absence of medical management of HF.
Diagnosis of CKD
Diagnosis of CKD was supported by history, clinical examina-
tion, imaging, biochemistry, and urinalysis that were performed on
the basis of the clinical presentation. Dogs were considered aﬀected
by CKD when a history of polyuria and polydipsia was conﬁrmed
by low urine speciﬁc gravity (<1.020) and at least 1 of the following:
fasting sCr, assessed on at least 2 occasions in a stable patient, was
above the reference range (sCr <1.4 mg/dL) increased sCr associated
with proteinuria and a previous diagnosis of CKD was reported in
the history. Fasting ≥8 h was considered adequate.
Echocardiography and ECG
All echocardiographic studies were performed using 2 ultra-
sound machine, both equipped with 5–7.5 MHz and 2.5–3 MHz,
multifrequency phased array transducers.b,c Dogs were consecu-
tively positioned in right and left lateral recumbency. All echocar-
diographic measurements were made on conscious dogs in
accordance with the guidelines of the American Society of
Echocardiography using the leading-edge to leading-edge method
for M-mode measurements and Hansson’s method for the
2-dimensional (2D) measurements of left atrial (LA) and aortic
root (Ao) diameters.13,14
From the right parasternal short-axis M-mode view at the chor-
dae level, the following variables were obtained: interventricular
septal thickness (IVS), left ventricular internal diameter (LVID),
and left ventricular posterior wall thickness (LVPW) in diastole
(d), and systole (s). The following variables were obtained from
2D views: Ao and LA from right parasternal short-axis view.
Mitral valve inﬂow (E peak velocity – EVmax, E/A ratio), aortic
peak velocity (AoVmax) and peak gradient (AoGmax), peak
velocity of mitral and tricuspid regurgitations (MR and TR) were
evaluated using the color Doppler and the spectral Doppler.15 The
following variables were calculated: left atrial-to-aortic root ratio
(LA/Ao), fractional shortening (FS%), left ventricular ejection
fraction (EF%), end systolic volume index (ESVI), end diastolic
volume index (EDVI), and normalized left ventricular end diastolic
diameter calculated according to Cornell’s method of allometric
scaling (LVEDDn).16 The EDVI and ESVI were calculated accord-
ing to the Teichholz formula, normalized to body surface area
(BSA). A standard 6-lead ECG was obtained in awake dogs to
assess heart rate and diagnose cardiac arrhythmias.
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MR peak velocity of mitral regurgitation
NTG no-treatment group
RBC red blood cells
s systole
SBP systolic blood pressure
sCr serum creatinine
TG treatment group
TR peak velocity of tricuspid regurgitation
UREA serum urea
WBC white blood cells
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Hematological and Biochemical Analyses
Data obtained from the CBC (white blood cell count [WBC],
red blood cell count [RBC], hemoglobin [Hb], hematocrit [Ht],
mean corpuscular volume [MCV], mean corpuscular hemoglobin
[MCH], mean corpuscular hemoglobin concentration [MCHC]),
UREA, sCr, and blood urea concentration (BUN)/sCr ratio
were recorded. Reference intervals for canine UREA and sCr
were 20–60 mg/dL and <1.4 mg/dL, respectively. Dogs were
grouped according to sCr (www.iris.kidney.com) as azotemic
(sCr ≥1.4 mg/dL) and nonazotemic (sCr <1.4 mg/dL); and
according to Hb concentration as anemic (Hb <12.9 g/dL)
and nonanemic (Hb ≥12.9 g/dL; using laboratory reference
intervals).
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 20
and C5.0. Baseline descriptive statistics were presented as mean
and standard deviation for normally distributed continuous vari-
ables, whereas non-normally distributed variables were presented
as median and interquartile (IQ) range. Normality of the distribu-
tion was tested using nonparametric Kolmogorov-Smirnov tests.
Data were analyzed using Student’s t-tests to investigate diﬀer-
ences between sets of data and simple or multiple ordinal regres-
sion tests to describe the relationships between dependent and
independent variables. Categorical variables were analyzed using
Chi-Square analysis. A P value <.05 was considered signiﬁcant.
The considered dependent variables were ACVIM class, IRIS
stage, UREA, and sCr. The independent variables were: all evalu-
ated echocardiographic variables, body weight (BW), body surface
area (BSA), heart rate (HR), systolic blood pressure (SBP), mur-
mur grade, treatment versus no-treatment (based on the adminis-
tration of furosemide), the total dose of furosemide administered
(mg/kg/day), and CBC variables. Using the C5.0 software, we
developed decision trees and rules sets with the aim of providing
veterinarians clinical guidelines to be followed whenever new
patients are presented.d
Investigators or trained senior veterinary students conducted
telephone interviews with dog owners or reviewed medical records
to determine the clinical outcome of each dog. Information
obtained was: was the dog dead or alive, had the dog been eutha-
nized or died spontaneously and reasons for euthanasia. In the
case of spontaneous death, the possible causes, including cardiac-
related sudden death, presence of syncope, or progression of HF
were determined. Cardiac-related death was deﬁned as death
occurring because of progression of clinical signs of HF. Euthana-
sia because of refractory HF was scored as cardiac-related death.
Sudden death was regarded as cardiac-related if no other cause of
death was identiﬁed.
Survival time was counted from the day of diagnosis of CMVD
to either the day of death or closing time of the study (June 1,
2014). The end-point of the study was cardiac death.
Dogs still alive at the end of the study period and dogs that
died of noncardiac disease were right-censored.
Dogs were sorted into groups (azotemic versus nonazotemic
and anemic versus nonanemic) to compare survival times. The
Kaplan-Meier method was used to estimate survival function and
plot time to event curves in the diﬀerent groups; equality of sur-
vival distributions was tested by the Log Rank method.
Eﬀects on survival of the following variables at baseline were
evaluated: ACVIM class, IRIS stage, presence or absence of ane-
mia, UREA, age at diagnosis, BW, treatment of heart failure (yes/
no), LVEDDn, and LA/Ao. Simple and multiple Cox proportional
hazard analysis was performed in order to determine the eﬀect of
any variable on survival.
Results
Population Characteristics and Descriptive Statistics
Of the 2271 dogs evaluated, 48% had CMVD.
Among them, 158 dogs of both sexes (94 males and 64
females) fulﬁlled the inclusion criteria and were enrolled
in the study. Of these, 20% of males and 65% of
females were neutered. They were between 5 and
17 years old (median age, 11.56; IQ range, 2.51 years),
with BW ranging from 2 to 48 kg (median age, 8.5; IQ
range, 8 kg). The most commonly represented breeds
were mongrel (42%), miniature Poodle (10%), York-
shire Terrier (10%), Shih-Tzu (6%), Doberman Pin-
scher (5%), and Dachshund (5%). In the group (TG)
(including 70.9% of the patients) 64% received furose-
mide and an angiotensin converting enzyme (ACE) inhi-
bitor (benazepril or enalapril) and 36% received triple
treatment with furosemide, an ACE inhibitor, and
pimobendan. The ACE inhibitor and pimobendan were
administered at standard dosage (benazepril, 0.25–
0.5 mg/kg q12h; enalapril, 0.5 mg/kg q12h; pimoben-
dan, 0.25–0.35 mg/kg q12h), whereas furosemide was
administered according to the severity of heart disease
(3.7  2.5 mg/kg/day). Echocardiographic results are
reported in Table 1. Dogs were classiﬁed as follow:
20.9% ACVIM B1, 9.5% ACVIM B2, 67.1% ACVIM
C, and 2.5% ACVIM D.
Among dogs with CHF, 74.7% were nonazotemic
and 25.3% were azotemic (12.6% in IRIS stage 2,
11.4% in IRIS stage 3, and 1.3% in IRIS stage 4). The
nonazotemic group included: 87.9% of ACVIM B1
dogs, 100% of ACVIM B2 dogs, 67.9% of ACVIM C
dogs, and 50% of ACVIM D dogs (Fig 1). The nona-
zotemic group represented more often than the azotemic
group in all ACVIM classes, but the frequency of IRIS
stage 2 and 3 was higher in ACVIM classes C and D.
The prevalence of CKD associated with azotemia in
dogs with CMVD was 25%. The prevalence of CKD in
symptomatic dogs (ACVIM classes C and D) was 32%.
The prevalence of CKD was signiﬁcantly higher in
the TG than in the no-treatment group NTG (32% ver-
sus 1%, P < .001). The mean sCr and UREA concen-
trations were signiﬁcantly higher in the TG than in the
NTG (sCr mean, 1.5 mg/dL versus 1.0 mg/dL,
P < .001; UREA mean, 83.8 mg/dL versus 58.7 mg/dL,
P = .006). The prevalence of anemia was 15%. There
were no diﬀerences among the prevalence of anemia in
diﬀerent ACVIM classes and no diﬀerence between the
TG and the NTG. The prevalence of anemia was signif-
icantly higher in the azotemic group than in the nona-
zotemic group (40% vs 10%, P = .04) and higher in
advanced IRIS stage (37% IRIS 3 vs 17% IRIS 2,
P = .02).
Inferential Statistics
The statistically signiﬁcant correlations between the
considered variables are reported in Table 2. Simple
ordinal regression showed that an increase in IRIS stage
led to an increase in the probability of being in a higher
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ACVIM class (odds ratio [OR], 2.5, 95%; conﬁdence
interval [CI], 1.4, 4.5; proportional odds assumption
met), and that an increase in ACVIM class led to an
increase in the probability of being in a higher IRIS
stage.
Survival Analysis
At the end of the follow-up period, 45 dogs (28%)
died or were euthanized because of refractory cardiac
disease, 48 dogs (30%) died of noncardiac causes, 42
dogs (26%) were still alive, and 23 (14%) dogs were lost
at follow-up. Median time to death for dogs with car-
diac death was 12 months (IQ range, 23.5 months) and
median time to death for noncardiac death was
11 months (IQ range, 24.5 months). Of the 9 variables
used as predictors in the univariate analysis, LA/Ao,
(Hazard ratio [Hr], 3.26; CI, 1.2–5.3; P = <.001), age at
diagnosis (Hr, 1.22; CI, 1.06–1.4; P = .005), IRIS stage
(Hr, 1.57; CI, 1.1–2.2; P = .01), LVEDDn (Hr, 3.01;
CI, 1.57–5.8; P = .001), furosemide versus no-treatment
(Hr, 2.87; CI, 1.33–6.2; P = .007), ACVIM class (Hr,
2.03; CI, 1.31–3.16; P = .002), and azotemic status (Hr,
2.56; CI, 1.36–4.8; P = .004) were associated with worse
outcomes. Results of the univariate Cox proportional
hazard regressions are shown in Table 3.
The presence of increased LA/Ao (Hr, 3.38; CI,
1.50–7.65; P = .003) and age at diagnosis (Hr, 1.2; CI,
1.02–1.4; P = .024) remained the only signiﬁcant predic-
tors of poor outcome in the multivariate analysis, even
after introducing an interaction term for variables for
which the proportional hazard assumption was not met.
Survival time was statistically diﬀerent between azote-
mic dogs versus nonazotemic dogs, and between dogs
with CvRD and dogs with CMVD, whereas there was
no diﬀerence in survival time when anemic dogs and
nonanemic dogs were compared (Figure 2).
Table 1. Echocardiographic parameters in 158 dogs
aﬀected by CMVD.
n Min Max
Mean or
median
St.dev or IQ
range
HR (bpm) 49 80 240 146 40
IVSd (mm) 151 3.40 18.00 7.70 2.70
LVIDd (mm) 151 16.60 74.70 35.70 13.10
LVPWd (mm) 151 4.10 15.10 7.20 2.10
IVSs (mm) 151 4.40 19.80 11.00 3.30
LVIDs (mm) 152 7.90 53.00 19.80 8.80
LVPWs (mm) 151 6.50 18.60 11.20 3.90
EF% 151 30.10 94.99 75.51 12.85
FS% 151 14.20 68.83 42.54 8.81
ESVI
(mL/m2)
152 3.76 182.59 28.31 20.90
EDVI
(mL/m2)
151 24.48 549.60 119.33 69.42
Ao (mm) 149 7.10 30.20 14.40 5.30
LA (mm) 149 11.80 66.00 29.00 12.40
LA/Ao 149 0.75 4.85 1.87 0.75
Evmax (m/s) 106 0.42 1.92 1.01 0.62
E/A 101 0.50 2.95 1.23 0.80
AoVmax (m/s) 100 0.67 3.76 1.22 0.36
AoGmax
(mmHg)
100 1.80 14.14 5.91 3.43
MR (m/s) 123 3.08 6.86 5.38 0.69
TR (m/s) 80 1.31 5.09 2.75 0.98
Heart Rate (HR), Interventricular septal thickness (IVS), left
ventricular internal diameter (LVID), and left ventricular posterior
wall thickness (LVPW) in diastole (d) and systole (s). Fractional
shortening (FS%), left ventricular ejection fraction (EF%),
Endsystolic volume index (ESVI), Enddiastolic volume index
(EDVI). Aortic root diameter (Ao), left atrial diameter (LA), left
atrial to aortic root ratio (LA/Ao). Mitral valve inﬂow (E peak
velocity—EVmax, E/A ratio), aortic peak velocity (AoVmax) and
peak gradient (AoGmax), peak velocity of mitral and tricuspid
regurgitations (MR and TR). Data have been ordered as com-
monly stored during echocardiography.
Fig 1. Distribution of serum creatinine concentrations observed in 158 dogs aﬀected by CMVD according to ACVIM classiﬁcation. The
dotted lines represent the IRIS staging system cutoﬀ values of 1.4 mg/dL, 2 mg/dL, and 5 mg/dL. The nonazotemic group (sCr < 1.4 mg/
dL) was more represented than the azotemic group (sCr ≥ 1.4 mg/dL) in all the ACVIM classes. Number of dogs in each ACVIM class:
33 dogs in B1, 15 dogs in B2, 104 dogs in C, 4 dogs in D. Dogs in IRIS stage 4 were censored to better display data (2 dogs censored).
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Discussion
The studied population was representative of the gen-
eral population of dogs aﬀected by CMVD (older dogs
of small and medium size breeds). The prevalence of
CKD complicating CMVD in the studied population
was signiﬁcantly higher than the prevalence of CKD in
the general population of dogs evaluated at the Univer-
sity of Milan (25% versus 15%, P < .0001; unpublished
data) and higher than the prevalence of CKD reported
by others (0.05–5.8%).17,18 The prevalence of CKD in
symptomatic dogs was lower than the prevalence
reported in human medicine (32% vs 45–63%). The
inﬂuence of CMVD on the prevalence of CKD suggests
an inﬂuence of heart disease on renal function.
Previously published prevalences of azotemia in dogs
with CMVD were 7.4, 24.1, and 14.5%.a,7,19 The diﬀer-
ences reported by diﬀerent investigators could be
explained by the diﬀerent percentages of dogs with
decompensated heart failure included in the studies.
Unfortunately, diﬀerences in the deﬁnition of azotemia
and HF classiﬁcations make it diﬃcult to compare data.
Table 2. Statistically signiﬁcant correlations between
renal function indicators and other variables.
Correlation
Spearmann’s
coeﬃcient P value
UREA-Furosemide (mg/kg/day) 0.31 <.001
UREA-IRIS 0.55 <.001
UREA-sCr 0.57 <.001
UREA Treatment versus NO-Treatment 0.18 .02
UREA-ACVIM 0.19 .02
UREA-SBP 0.59 .06
UREA-WBC 0.15 .07
sCr-ACVIM 0.29 <.001
sCr Treatment versus NO-Treatment 0.31 <.001
sCr-Murmur Grade 0.23 .01
sCr-WBC 0.18 .04
sCr-SBP 0.52 .10
sCr-Hb 0.11 .21
sCr-MCHC 0.08 .36
ACVIM-BW 0.23 <.001
ACVIM-Furosemide (mg/kg/day) 0.28 <.001
ACVIM-ESVI 0.37 <.001
ACVIM-E/A 0.42 <.001
ACVIM-Murmur Grade 0.46 <.001
ACVIM-EDVI 0.56 <.001
ACVIM- LVEDDn 0.57 <.001
ACVIM-Evmax 0.62 <.001
ACVIM-LA/Ao 0.66 <.001
ACVIM Treatment versus NO-Treatment 0.95 <.001
ACVIM-MR 0.25 .01
ACVIM-HR 0.37 .01
ACVIM-TR 0.27 .02
IRIS Treatment versus NO-Treatment 0.26 <.001
IRIS-LA/Ao 0.23 .01
IRIS-LVEDDn 0.21 .01
IRIS-HR 0.32 .02
IRIS-WBC 0.15 .07
IRIS-Hb 0.09 .27
Serum urea (UREA), serum creatinine (sCr), body weight (BW),
heart rate (HR), systolic blood pressure (SBP), white blood cells
(WBC), hemoglobin (Hb), mean corpuscular hemoglobin concen-
tration (MCHC), End systolic volume index (ESVI), End diastolic
volume index (EDVI), normalized left ventricular end diastolic
diameter (LVEDDn), left atrial to aortic root ratio (LA/Ao),
mitral valve inﬂow (E peak velocity—EVmax, E/A ratio), peak
velocity of mitral and tricuspid regurgitations (MR and TR).
Table 3. Univariate Cox regressions results.
Sig.
Hazard
ratio
95% CI for
Exp(B)
Lower Upper
LA/Ao* <0.001 3.259 1.995 5.324
LVEDDn 0.001 3.015 1.569 5.795
Treatment versus
NO-Treatment
0.007 2.87 1.328 6.203
AZOTEMIC 0.004 2.559 1.358 4.821
ACVIM 0.002 2.033 1.307 3.162
IRIS 0.01 1.571 1.115 2.212
Age at Diagnosis* 0.005 1.223 1.064 1.405
UREA 0.073 1.004 1 1.007
ANEMIA 0.651 0.759 0.23 2.504
We checked for the proportionality of hazards assumption by
plotting LogMinusLog curves (for ordinal variables) and Schoen-
feld residuals (for scalar variables). For those variables (marked
with *) which did not meet the assumption, the hazard ratio has
to be considered only a pooled value.
C
um
S
ur
vi
va
l
1,0
0,8
0,6
0,4
0,2
0,0
Time to death (months)
12010896847260483624120
Survival Functions
CRS-censored
CMVD-censored
CRS
CMVD
Fig 2. Comparison of survival time between dogs aﬀected by
CRS and dogs with CMVD. Blue: dogs aﬀected by CMVD.
Green: dogs with CRS. Survival time was statistically diﬀerent
between dogs with CRS versus dogs with CMVD (P = .002). End-
point of the study was cardiac death. Dogs still alive at the end of
the study period and dogs that died of noncardiac disease were
right-censored. The Kaplan-Meier method was used to estimate
survival function and plot time to event curves in the diﬀerent
groups and equality of survival distributions was tested by Log
Rank.
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The connection between class of cardiac failure and
class of kidney disease was conﬁrmed by the statistically
signiﬁcant correlation found between the two variables
(P = .003). Advanced ACVIM class could be predictive
of advanced IRIS stage and vice versa. This ﬁnding, as
well as the statistically signiﬁcant correlation found
between ACVIM and both UREA and sCr, is of clini-
cal importance in the management of patients with sev-
ere heart disease. Furthermore, the 33% of dogs in
congestive HF with concomitant azotemia require speci-
ﬁc management.
The IRIS stages directly correlated with the echocar-
diographic variables of heart enlargement (LA/Ao and
LVEDDn) suggesting a direct connection between car-
diac remodeling and renal impairment. The ACVIM
class showed a statistically signiﬁcant correlation with
the echocardiographic variables of heart enlargement
(LA/Ao, EDVI, and LVEDDn), with Doppler variables
related to diastolic function (EVmax and E/A), with
MR (systolic left ventricle impairment and high LA
pressure decrease MR in advanced heart disease), with
TR (which is an indirect evaluation of systolic pul-
monary arterial pressure that increases with heart fail-
ure class), with HR (worsening heart disease induces
sympathetic system activation), and with murmur grade,
as recently reported in the veterinary literature.20,21 The
direct correlation found between UREA, sCr, and SBP
could be explained considering that in dogs aﬀected by
CKD, renin-angiotensin-aldosterone system (RAAS)
activation leads to water and salt retention and increas-
ing SBP.
Despite demographic risk factors previously identiﬁed
for CKD including small body size, no statistically sig-
niﬁcant correlation was seen between IRIS stage and
BW or BSA.18 This unexpected result suggests that
body size does not seem to inﬂuence CKD severity,
whereas it may inﬂuence HF severity.
Treatment seems to inﬂuence renal function by
increasing UREA, sCr, and IRIS stage even if these
results probably are aﬀected by the most severe car-
diac condition in dogs requiring medical management
of HF (severe heart disease require high furosemide
dosage administration, and these 2 conditions are
inseparables). The amount of furosemide administered
was directly correlated with UREA, but not with
IRIS stage and sCr. This ﬁnding could be explained
by considering that the amount of furosemide admin-
istered increases with worsening cardiac function. In
situations of compromised renal blood ﬂow, as with
advanced cardiac disease, decreased ﬂow rate in the
tubules allows more time for urea reabsorption. The
increased reabsorption of urea from within the renal
tubule leads to UREA increasing disproportionately
to sCr.19,22,23
Considering that an increase in UREA with a nor-
mal sCr is most likely consistent with a prerenal azote-
mia, the serum BUN/sCr ratio has been suggest to
diﬀerentiate prerenal and renal azotemia.24 In our
study, the BUN/sCr ratio was not correlated with any
ACVIM class or IRIS stage. Thus, according to
previously published data, the BUN/sCr ratio alone
cannot be used to distinguish renal from prerenal azo-
temia.25 Distinguishing renal from prerenal azotemia
still is a challenge in dogs with cardiac disease because
of the unreliability, in patients receiving diuretics, of
the urine speciﬁc gravity.
Hemoglobin was negatively correlated with sCr and
IRIS stage, conﬁrming the existence of a link between
renal impairment degree and anemia. No correlation
was found between anemia and classes of HF, support-
ing the previous ﬁnding of a lack of correlation between
anemia and ACVIM classiﬁcationa. Patients in more
advanced ACVIM class were characterized by higher
HR, probably because of an increased sympathetic
tone. The direct correlation found between HR and
IRIS stage could be explained by considering that
advanced IRIS stages are correlated with anemia and
decreased Hb concentration that induce sympathetic
system activation and increase HR.
The presence of azotemic dogs in ACVIM class B1
(12.1%) suggests the existence, in some dogs included in
this study, of primary renal damage. This ﬁnding high-
lights the diﬃculties of distinguishing CRS type 2 from
type 4 patients. Furthermore, in some patients renal
impairment and CMVD probably coexisted. Regardless
of these considerations, the presence of advanced heart
disease, advanced renal disease or both, furosemide
administration (correlated with advanced ACVIM class)
and advanced age at diagnosis of heart disease all
decrease survival time. A key point in our results is the
diﬀerence in life expectancy between the analyzed
groups: the survival time of dogs aﬀected by CvRD was
statistically lower than the survival time of dogs aﬀected
by CMVD alone.
The main limitations of this study relate to its retro-
spective nature. As commonly reported in human medi-
cine, CRS Type 2 and type 4 patients could not be
clearly diﬀerentiated. Moreover, to improve the reliabil-
ity of our study, we applied strict inclusion criteria that
decreased sample size. Therefore, small sample size and
underrepresentation of ACVIM class B2 could have
aﬀected some results. The lack of biomarkers of early
renal injury, of urine examination and of abdominal
ultrasound examination in all cases probably led to an
underestimation of the prevalence of CKD.
Clinical Relevance
The prevalence of CKD and anemia in dogs with
CMVD was signiﬁcantly higher than the prevalence in
the general population of dogs. Medical management
of HF aﬀects the prevalence of CKD. The ACVIM
class and IRIS stage were directly correlated. Cardio-
vascular–renal disorder decreases survival time com-
pared to the presence of CMVD alone, whereas
anemia does not seem to play a central role in worsen-
ing heart function. Further investigations are needed to
determine if CMVD or administration of drugs for
medical management of HF can adversely aﬀect renal
function.
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Footnotes
a Ohad DG, Berkowitz J, Bdolah-Abram T. Is the cardiorenal-
anemia syndrome prevalent in dogs? (abstr), ACVIM congress
2010. J Vet Intern Med 2010;24:672
b Esaote Medical System, Megas Esaote Cvx
c Esaotte Medical System, Esaote MyLab50
d Release 2.07 GPL Edition
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